Mawer Investment Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-51,912
| Closed | -$7.81M | – | 111 |
|
|
2025
Q1 | $7.81M | Buy |
51,912
+5,283
| +11% | +$795K | 0.04% | 97 |
|
|
2024
Q4 | $8.61M | Buy |
46,629
+5,769
| +14% | +$1.06M | 0.04% | 93 |
|
|
2024
Q3 | $8.05M | Sell |
40,860
-32,693
| -44% | -$6.44M | 0.04% | 97 |
|
|
2024
Q2 | $15.2M | Buy |
73,553
+27,954
| +61% | +$5.77M | 0.07% | 79 |
|
|
2024
Q1 | $12.4M | Buy |
45,599
+19,574
| +75% | +$5.3M | 0.06% | 78 |
|
|
2023
Q4 | $6.15M | Buy |
26,025
+7,014
| +37% | +$1.66M | 0.03% | 78 |
|
|
2023
Q3 | $3.73M | Buy |
19,011
+1,744
| +10% | +$342K | 0.02% | 83 |
|
|
2023
Q2 | $3.63M | Buy |
17,267
+1,434
| +9% | +$301K | 0.02% | 81 |
|
|
2023
Q1 | $3.2M | Buy |
15,833
+500
| +3% | +$101K | 0.02% | 84 |
|
|
2022
Q4 | $3.34M | Buy |
15,333
+2,766
| +22% | +$603K | 0.02% | 85 |
|
|
2022
Q3 | $2.47M | Buy |
12,567
+3,644
| +41% | +$717K | 0.02% | 81 |
|
|
2022
Q2 | $1.91M | Buy |
8,923
+2,951
| +49% | +$631K | 0.01% | 81 |
|
|
2022
Q1 | $1.7M | Buy |
5,972
+3,040
| +104% | +$863K | 0.01% | 85 |
|
|
2021
Q4 | $1.11M | Buy |
2,932
+1,919
| +189% | +$723K | 0.01% | 96 |
|
|
2021
Q3 | $418K | Buy |
+1,013
| New | +$418K | ﹤0.01% | 98 |
|